Merck & Co Inc (Symbol: MRK) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Here are seven pharmaceutical stocks to buy with dividends of at least 2%, according to Bank of America: ...

Behind negative returns for shares of American Express and Merck, the Dow Jones Industrial Average is declining Friday morning.

Shares of Merck & Co. Inc. MRK slumped 0.79% to $109.40 Thursday, on what proved to be an all-around rough trading session ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Deep-pocketed investors have adopted a bearish approach towards Merck & Co MRK, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an antibody-drug ...

**NM signifies a non meaningful value. A dash signifies the data is not available.